Clinical Significance of Aortic Root Modification Associated With Bicuspid Aortic Valve in Marfan Syndrome.


Journal

Circulation. Cardiovascular imaging
ISSN: 1942-0080
Titre abrégé: Circ Cardiovasc Imaging
Pays: United States
ID NLM: 101479935

Informations de publication

Date de publication:
03 2019
Historique:
entrez: 8 3 2019
pubmed: 8 3 2019
medline: 6 2 2020
Statut: ppublish

Résumé

Both bicuspid aortic valve (BAV) and Marfan syndrome have been associated with aortic dissection risk, but it is unknown whether the presence of BAV is associated with an increased aortic risk in patients with an FBN1 gene mutation. We evaluated aortic diameters, aortic valve function, and aortic shape in Marfan syndrome patients with and without BAV and reported aortic events during follow-up. All patients with an FBN1 gene mutation evaluated in our clinic were included. Aortic root diameters were measured, and the aortic valve was studied using echocardiography at each visit. Of the 1437 patients with an FBN1 gene mutation, 26 patients (1.8%) had a BAV. Both aortic root maximal diameter and normalized Z score were larger at all ages, in patients with BAV when compared with patients with tricuspid aortic valve. Prophylactic aortic root surgery tended to be performed in younger patients when BAV was present, although aortic diameter threshold was similar in the 2 populations. No aortic dissection was observed in Marfan syndrome patients with BAV. In patients with a FBN1 mutation, BAV is associated with larger aortic root diameter, with no difference in evolution of Z score with age. We found a trend towards prophylactic aortic root surgery at younger ages but similar aortic diameter thresholds without occurrence of aortic dissection. We did not find any evidence for lowering aortic diameter thresholds used to propose preventive aortic root surgery in the presence of BAV in patients with FBN1 mutations.

Sections du résumé

BACKGROUND
Both bicuspid aortic valve (BAV) and Marfan syndrome have been associated with aortic dissection risk, but it is unknown whether the presence of BAV is associated with an increased aortic risk in patients with an FBN1 gene mutation. We evaluated aortic diameters, aortic valve function, and aortic shape in Marfan syndrome patients with and without BAV and reported aortic events during follow-up.
METHODS
All patients with an FBN1 gene mutation evaluated in our clinic were included. Aortic root diameters were measured, and the aortic valve was studied using echocardiography at each visit.
RESULTS
Of the 1437 patients with an FBN1 gene mutation, 26 patients (1.8%) had a BAV. Both aortic root maximal diameter and normalized Z score were larger at all ages, in patients with BAV when compared with patients with tricuspid aortic valve. Prophylactic aortic root surgery tended to be performed in younger patients when BAV was present, although aortic diameter threshold was similar in the 2 populations. No aortic dissection was observed in Marfan syndrome patients with BAV.
CONCLUSIONS
In patients with a FBN1 mutation, BAV is associated with larger aortic root diameter, with no difference in evolution of Z score with age. We found a trend towards prophylactic aortic root surgery at younger ages but similar aortic diameter thresholds without occurrence of aortic dissection. We did not find any evidence for lowering aortic diameter thresholds used to propose preventive aortic root surgery in the presence of BAV in patients with FBN1 mutations.

Identifiants

pubmed: 30841707
doi: 10.1161/CIRCIMAGING.118.008129
doi:

Substances chimiques

FBN1 protein, human 0
Fibrillin-1 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e008129

Commentaires et corrections

Type : CommentIn

Auteurs

Olivier Milleron (O)

Centre National de Référence pour le syndrome de Marfan et apparentés, Paris, France (O.M., F.A., C. Bouleti, G.D., M.L., M.T., C. Boileau, G.J.).
AP-HP, Hôpital Bichat, Service de Cardiologie, Paris, France (O.M., C. Bouleti, G.J.).
DHU Fire, Paris-Diderot University, France (O.M., C. Bouleti, C. Boileau, G.J.).
INSERM LVTS U1148 75018 Paris (O.M., C. Bouleti, C. Boileau, G.J.).

Jacques Ropers (J)

AP-HP, Hôpital Pitié- Salpêtrière, Unité de Recherche Clinique, Paris, France (J.R.).

Florence Arnoult (F)

Centre National de Référence pour le syndrome de Marfan et apparentés, Paris, France (O.M., F.A., C. Bouleti, G.D., M.L., M.T., C. Boileau, G.J.).
AP-HP, Hôpital Bichat, Service d'explorations fonctionnelles, Paris, France (F.A.).

Claire Bouleti (C)

Centre National de Référence pour le syndrome de Marfan et apparentés, Paris, France (O.M., F.A., C. Bouleti, G.D., M.L., M.T., C. Boileau, G.J.).
AP-HP, Hôpital Bichat, Service de Cardiologie, Paris, France (O.M., C. Bouleti, G.J.).
DHU Fire, Paris-Diderot University, France (O.M., C. Bouleti, C. Boileau, G.J.).
INSERM LVTS U1148 75018 Paris (O.M., C. Bouleti, C. Boileau, G.J.).

Gabriel Delorme (G)

Centre National de Référence pour le syndrome de Marfan et apparentés, Paris, France (O.M., F.A., C. Bouleti, G.D., M.L., M.T., C. Boileau, G.J.).

Maud Langeois (M)

Centre National de Référence pour le syndrome de Marfan et apparentés, Paris, France (O.M., F.A., C. Bouleti, G.D., M.L., M.T., C. Boileau, G.J.).

Maria Tchitchinadze (M)

Centre National de Référence pour le syndrome de Marfan et apparentés, Paris, France (O.M., F.A., C. Bouleti, G.D., M.L., M.T., C. Boileau, G.J.).

Celine Guien (C)

Aix Marseille University, INSERM, GMGF, Marseille, France (C.G. C. Beroud).

Christophe Beroud (C)

Aix Marseille University, INSERM, GMGF, Marseille, France (C.G. C. Beroud).
AP-HM, Département de Génétique Médicale, Hôpital Timone Enfants, Marseille, France (C. Beroud).

Catherine Boileau (C)

Centre National de Référence pour le syndrome de Marfan et apparentés, Paris, France (O.M., F.A., C. Bouleti, G.D., M.L., M.T., C. Boileau, G.J.).
DHU Fire, Paris-Diderot University, France (O.M., C. Bouleti, C. Boileau, G.J.).
INSERM LVTS U1148 75018 Paris (O.M., C. Bouleti, C. Boileau, G.J.).
AP-HP, Hôpital Bichat, Service de génétique, Paris, France (C. Boileau).

Guillaume Jondeau (G)

Centre National de Référence pour le syndrome de Marfan et apparentés, Paris, France (O.M., F.A., C. Bouleti, G.D., M.L., M.T., C. Boileau, G.J.).
AP-HP, Hôpital Bichat, Service de Cardiologie, Paris, France (O.M., C. Bouleti, G.J.).
DHU Fire, Paris-Diderot University, France (O.M., C. Bouleti, C. Boileau, G.J.).
INSERM LVTS U1148 75018 Paris (O.M., C. Bouleti, C. Boileau, G.J.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH